SEC Form 4 · accession 0000899243-17-007839
ZOGENIX, INC. · ZGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thierry J.P. Darcis
Officer — EVP / General Manager, Europe
Period of report
Mar 14, 2017
Accepted (ET)
Mar 16, 2017 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001375151
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.20 | Mar 14, 2017 | A | 52,500 | A | — | Mar 13, 2027 | Common Stock | 52,500 | 52,500 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 14, 2017 | A | 8,750 | A | — | Mar 13, 2022 | Common Stock | 8,750 | 8,750 | D |
Explanation of responses
- F1The option was granted on March 14, 2017 and vests in a series of forty-eight (48) successive, equal monthly installments beginning on April 14, 2017, subject to the reporting person's continued employment with the Company on each vesting date.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of ZGNX common stock.
- F3The RSUs shall vest upon the approval by the U.S. Food and Drug Administration of the Company's New Drug Application for ZX008, provided such approval occurs within five years following the grant date, subject to the option recipient's continuous service to the Company on such vesting date.